RxDoctor Payments Data

James Loos, MD

Urology · Medford, ORNPI 1801991476

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,993 of the $2,998 with a category attached, or 66.5%. 22 manufacturers reported payments, led by Procept Biorobotics Corporation at 37.5% of the total. Reporting peaked in 2024 at $1,417 and has fallen 74.8% since, to $357 in 2025.

$2,998in general payments, 2019–2025

Across 96 payments — averaging $31.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$1K
  • AbbVie$355
  • Boston Scientific$230
  • Johnson & Johnson$212
  • Pfizer$157
  • Coloplast$144
  • plus $775 from 16 others

What the payments were for

  • Travel & lodging$90630%
  • Food & beverage$1,99366%
  • Education$993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,998 in reported general payments places this provider in the 65th percentile of 153 urology providers in Oregon.

See all urology providers in Oregon

Medicare billing

Part B allowed, 2024
$264,390
Medicare patients
551
Services billed
7,833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide12$198,776
MyrbetriqMirabegron32$24,369
Tamsulosin Hcl534$11,546
Potassium Citrate ErPotassium Citrate53$5,737
Testosterone Cypionate67$3,170
Finasteride163$2,895
Testosterone12$1,787
Trospium Chloride16$1,614
Alfuzosin Hcl ErAlfuzosin Hcl36$1,338
Silodosin22$1,269
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst39$973
Oxybutynin Chloride ErOxybutynin Chloride21$741
Cephalexin48$586
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen85$555
Methenamine Hippurate15$401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$97$223,14544 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 153 urology providers in Oregon.

Other urology in Medford

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →